Topic: Fluvoxamine

Dr. Haider explains the mechanism of ivermectin, which blocks viral entry and reduces inflammation, but notes that newer variants require higher doses and combination therapies. He recommends a "cocktail" including hydroxychloroquine and fluvoxamine (Prozac), explaining that fluvoxamine prevents platelets from dumping serotonin, which triggers the dangerous cytokine storm. These protocols are suggested even for those suffering from vaccine injuries or long-term spike protein inflammation.

Dr. Saeed Haider joins the studio to discuss the efficacy of Fluvoxamine, an SSRI, in reducing COVID-19 mortality by up to 12 times. He explains how the drug can prevent cytokine storms and stabilize platelets. Dr. Haider also reports that the FDA and USPS are allegedly colluding to seize overseas shipments of Ivermectin intended for American citizens.

Dr. Haider explains that Fluvoxamine and Prozac act on the sigma-1 receptor to provide anti-inflammatory and antiviral effects against COVID-19. He notes that while Johns Hopkins has included Fluvoxamine in its guidelines, the NIH and FDA have not. The segment highlights the work of Steve Kirsch in bankrolling clinical trials and the difficulty of finding pharmaceutical companies willing to support off-patent, low-cost treatments.

Dr. Haider explains that Ivermectin and Fluvoxamine are synergistic; Ivermectin blocks the spike protein from entering cells, while Fluvoxamine addresses inflammation within the brain. He clarifies that Ivermectin is used for its antiviral properties in COVID-19, not its anti-parasitic ones. He asserts that Ivermectin is one of the safest drugs in medical history, far safer than common over-the-counter medications like Tylenol.

In his final segment, Kirsch discusses the success of early treatment protocols using Ivermectin and Fluvoxamine, citing Japan's low death rates as evidence. He praises Nicole Belland, a pharmacist who quit her job rather than continue administering vaccines she believed were harmful. Kirsch concludes by reiterating that the Joe Rogan interviews with Malone and McCullough will likely "break the camel's back" for the vaccine narrative.

Despite a Phase 3 trial published in The Lancet showing fluvoxamine reduces COVID-19 deaths by 12 times, the NIH and WHO remain silent. Kirsch argues that the medical community is violating the Nuremberg Code by suppressing effective early treatments like ivermectin and hydroxychloroquine in favor of experimental injections.

For those suffering from "Long Hauler" syndrome, Dr. McCullough recommends the FLCCC "I-Recover" protocol, which utilizes ivermectin to antagonize the spike protein. He also mentions fluvoxamine as a drug showing promise in reducing the severity of neurologic symptoms and inflammation. McCullough emphasizes that while these are not yet proven in large randomized trials, they offer a conceptual framework for treating persistent spike protein damage.

Scott Miller explains the circulatory nature of COVID-19 and the importance of addressing clotting factors using N-acetylcysteine and aspirin. He also discusses the role of Fluvoxamine as an anti-serotonergic agent to decrease lung inflammation. The discussion criticizes the continued use of ventilators, which Miller and the host claim have high mortality rates for COVID-19 patients.